You are here
Family Bank: Cordlife Group Limited
Cordlife Group Limited owns and operates five cord blood laboratories in Singapore, Hong Kong, India, Indonesia and the Philippines. Cordlife was the first cord blood bank in Singapore (May 2001) and amongst the first in Asia. Cordlife Group Limited has more than 12 years of cord blood banking experience as well as a published track record of cord blood transplants.
Labs and Locations
Cordlife Group Limited
1 Yishun Industrial Street 1 #06-01/09,
A'Posh Bizhub Singapore 768160
Cordlife Group Limited is listed on the Mainboard of the Singapore Exchange (SGX), and together with its subsidiaries, may be called "The Group". Cordlife Group Limited owns five cord blood banks in Singapore, Hong Kong, Indonesia, Philippines and India, and has a direct investment in China Cord Blood Corporation, one of the top banks in China. Cordlife also currently owns over 30% of Stemlife Malaysia. At present the laboratories in Singapore, Hong Kong, and India are accredited by AABB (formerly known as American Association of Blood Banks), meeting the gold standard of private cord blood banking. The Group now comprises of:
Cordlife Group Limited - Singapore
Cordlife (Hong Kong) Limited - Hong Kong & Macau
Cordlife Sciences India Pvt Limited - Kolkata, India
PT Cordlife Persada - Jakarta, Indonesia
Cordlife Medical Philippines, Inc. - Manila, Philippines
Cordlife Group Limited was established in Singapore in 2001 to provide a full suite of cord blood and (subsequently) tissue banking services which include the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. Cordlife has grown rapidly from a fledging start-up company into a multi-national corporation. In 2005, Cordlife established its first overseas cord blood processing and storage facility in Hong Kong. The ISO certified facility, with a storage capacity for 50,000 cord blood and umbilical cord units, is Hong Kong’s largest and most advanced stem cell facility. In 2011, Cordlife introduced the patented technology, CellOptima™, which is exclusively available at Cordlife in Hong Kong, to isolate two types of stem cells from umbilical cord – Epithelial stem cells and Mesenchymal Stem Cells (MSC).
The kit contains a closed system blood bag (brand JMS) that is pre-loaded with the anti-coagulant CPDA-1. The kit also provides the disinfectant Povidone-iodine.
The collection kit is constructed with thermal insulation and validated to maintain room temperature for up to 48 hours during transportation back to the laboratory.
Cordlife provides dedicated staff to pick up the cord blood sample from Singapore hospitals upon notification.
Stem cells are separated from the cord blood using the fully automated and closed Sepax system from Biosafe. The final component is the buffy coat layer of the blood, which holds both white cells and stem cells.
Parents are provided with a report describing test results for the buffy coat holding white cells and stem cells including total nucleated cells (TNC), post processing sterility, viable CD34+ counts, as well as maternal blood infectious disease results.
Final cord blood storage is in 25 ml blood (cryo) bag encased in an overwrap. Blood samples are kept in a quarantine freezer, then moved to long term freezer after they pass testing. Stem cells are stored in the vapour phase of cryogenic nitrogen.
Licensing & Accreditation
Certified by Singapore Ministry of Health
Accredited by AABB
Accredited by FACT
Cordlife Singapore is the first bank in southeast Asia to achieve dual AABB & FACT accreditation
Cordlife Group Limited has released 11 client cords for therapy (6 autologous, 5 allogeneic)
Cordlife clients will be covered by a program known as the Cordlife Care360 – a holistic program aimed to safeguard our client and their family.
1) Cordlife provides the coverage of possible pregnancy and childbirth complications*.
2) Cordlife will cover future storage payments if death or total permanent disability* occurs to either biological parent of Child during the contractual storage period.
3) Cordlife assures clients a cord blood unit of suitable match or US$25,000 to defray medical costs if the cord blood loses its viability at point of transplant*.
4) Cordlife will cover the cost for additional tests required in the event of a transplant* - matching (HLA resolution test) and viability (CFU assay).
5) Cordlife has taken additional insurance coverage, to safeguard client and their family from financial loss resulting from direct malpractice*.
* Terms and Conditions apply
Free banking (terms and conditions apply) is given to families when a sibling has a diagnosis for which transplantation is standard therapy.
Special discounts are given to medical doctors and nurses.
2nd - 20th year
11th - 20th year
Cordlife has an exclusive license on patented technology to store stem cells from the lining of the umbilical cord. This cord lining contains both Epithelial Stem Cells (EpSC) and Mesenchymal Stem Cells (MSC). Parents who are banking cord blood can choose the enhanced services CordPlus (EpSCs + MSCs) or CordBasic plan (MSCs).